Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Clinical trial

NCT06203210

1 development in the corpus

NCT06203210

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 5, 2026 · PHASE 3 TRIAL

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

ClinicalTrials.gov

Phase 3 randomized trial of ifinatamab deruxtecan versus physician's choice in relapsed SCLC; registry record with no results posted, so efficacy and safety remain unreported.

PreliminaryNCT06203210 Amrubicin Topotecan

Reported

Planned enrollment540

Primary endpointOverall Survival (OS), from date of randomi…

PhasePhase 3

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support